🇺🇸 FDA

Company profile · Sponsor

Vertex

Vertex Pharmaceuticals (Ireland) Limited

VRTX · NYSE pharma BOSTON, MA, GB
Pipeline
24
Drugs
9
Patents
8

Quick answer

Vertex (VRTX) is a pharma company. headquartered in BOSTON, MA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 9 drugs, and 8 patents to this profile..

Company facts

Ticker VRTX
Exchange NYSE
Company type pharma
Headquarters BOSTON, MA, GB
SEC CIK 0000875320

Pipeline (24)

Search pipeline →

  1. Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet

    Vertex

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  2. Biological/Vaccine

    Vertex

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  3. CTX001

    Vertex

    Beta-Thalassemia

    phase 3 mab active

    1 trial

  4. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  5. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  6. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex

    Transfusion-dependent β-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  7. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN

    Vertex

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  8. ELX/TEZ/IVA

    Vertex

    Cystic Fibrosis

    phase 3 small molecule active

    19 trials

  9. Exa-cel

    Vertex

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial

  10. IVA

    Vertex

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  11. Ivacaftor

    Vertex

    Cystic Fibrosis

    phase 3 small molecule completed

    16 trials

  12. Kalydeco 150 mg film-coated tablets, VX-770 Film-coated tablet, Kalydeco 75 mg film-coated tablets, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, VX-770 Film-coated tablet, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination tablet, Kaftrio 75 mg/50 mg/100 mg film-coated tablets

    Vertex

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  13. Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kalydeco 59.5 mg granules in sachet, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-121/VX-661/VX-561 granules, VX-445/VX-661/VX-770 fixed-dose combination tablet, VX-121/VX-661/VX-561 Film-coated tablet, VX-121/VX-661/VX-561

    Vertex

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  14. LUM

    Vertex

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  15. Lumacaftor

    Vertex

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  16. Lumacaftor Plus Ivacaftor Combination

    Vertex

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  17. Lumacaftor Plus Ivacaftor Combination

    Vertex

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  18. MP-424

    Vertex

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  19. MP-424

    Vertex

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  20. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex

    Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  21. Pegylated Interferon Alfa 2a

    Vertex

    Infection

    phase 3 small molecule terminated

    1 trial

  22. Pegylated Interferon Alfa 2a

    Vertex

    Hepatitis C

    phase 3 mab completed

    1 trial

  23. Placebo

    Vertex

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  24. Povetacicept

    Vertex

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

Drugs (9)

Search drugs →

  1. deutivacaftor

    ALYFTREK

    ORAL approved

  2. deutivacaftor / tezacaftor / vanzacaftor

    ALYFTREK

    R07AX33

  3. elexacaftor, ivacaftor, tezacaftor

    TRIKAFTA (COPACKAGED)

    ORAL approved

  4. exagamglogene autotemcel

    CASGEVY

    B06AX05

  5. ivacaftor

    KAFTRIO

    ORAL approved

    R07AX32

  6. lumacaftor

    ORKAMBI

    R07AX30

  7. suzetrigine

    JOURNAVX

    ORAL approved

  8. telaprevir

    INCIVO

    ORAL approved

    J05AE

  9. tezacaftor

    SYMKEVI

    R07AX31

Patents (8)

Search patents →

  1. US 12421249

    Inhibitors of APOL1 and methods of using same

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12385013

    Differentiation of pancreatic endocrine cells

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12384790

    Pteridinone compounds and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12377252

    Implantation devices, system, and methods

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12371665

    Differentiation of pancreatic endocrine cells

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12350262

    Methods of treatment for cystic fibrosis

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Vertex?

Vertex (VRTX) is a pharma company. headquartered in BOSTON, MA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 9 drugs, and 8 patents to this profile..

What pipeline programs does Vertex sponsor?

We track 24 ClinicalTrials.gov-linked programs for Vertex, including Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Vertex company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.